Interim Results of the Phase 2b GALAXY Trial to be Presented at the Chemotherapy Foundation Symposium

  Interim Results of the Phase 2b GALAXY Trial to be Presented at the
  Chemotherapy Foundation Symposium

Business Wire

LEXINGTON, Mass. -- November 07, 2012

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that interim
results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy
Foundation Symposium in New York City on Friday, November 9 during the 11:45
a.m. session on new agents for lung cancer. Presenting this data at the
conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical
Oncology, and Director, Translational Thoracic Malignancies Program, of the
Winship Cancer Institute of Emory University.

The GALAXY trial is a Phase 2b/3 program designed to compare single agent
docetaxel versus docetaxel plus ganetespib, a potent and selective Hsp90
inhibitor, as second-line treatment of advanced non-small cell lung cancer.
The presentation will review prior results highlighted at the 2012 Congress of
the European Society for Medical Oncology (ESMO) last September.

About Ganetespib

Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) that is
structurally unrelated to first-generation, ansamycin-related Hsp90
inhibitors. In preclinical experiments, ganetespib has shown activity in
multiple tumor models both as a single agent and in combination with certain
widely used cancer agents. Company-sponsored clinical trials with ganetespib
include 1) the GALAXY Phase 2b/3 trial evaluating ganetespib in combination
with docetaxel as second-line treatment of non-small cell lung cancer (NSCLC),
2) the CHIARA Phase 2 trial evaluating ganetespib monotherapy in ALK+ NSCLC,
and 3) the ENCHANT Phase 2 trial evaluating ganetespib as first-line treatment
for HER2+ and triple-negative metastatic breast cancer. In addition,
ganetespib is being evaluated in investigator-sponsored trials including lung,
breast, prostate, gastric, pancreatic, and colorectal cancers as well as
ocular melanoma, acute myeloid leukemia and multiple myeloma. Information on
these trials can be found at www.clinicaltrials.gov.

About the GALAXY Trials™

The GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) program
consists of two randomized trials comparing the combination of ganetespib and
docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have
received one prior systemic therapy: a Phase 2b study to determine the patient
population most likely to derive benefit from ganetespib, and a Phase 3
pivotal trial enriched for this identified population, More information about
the GALAXY trials can be found at www.clinicaltrials.gov (NCT01348126).

About Hsp90

Hsp90 is a molecular chaperone required for the proper folding and activation
of many cancer-promoting proteins, and is recognized as a key facilitator of
cancer cell growth and survival. Many of the “client proteins” of Hsp90 – such
as ALK, AKT, BCR-ABL, BRAF, KIT, MET, EGFR, FLT3, HER2, HIF-1alpha, PDGFRA,
VEGFR are the targets of clinically validated cancer drugs. In preclinical
studies, inhibiting Hsp90 causes the degradation of multiple client proteins
and leads to cancer cell death.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including
cancer and chronic inflammatory diseases. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities. For more
information, please visit www.syntapharma.com.

Safe Harbor Statement

This media release contains forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified by the
use of forward-looking terminology such as "will", "would", "should",
"expects", "anticipates", "intends", "plans", "believes", "may", "estimates",
"predicts", "projects", or similar expressions intended to identify
forward-looking statements. Such statements, including statements relating to
the timing, developments and progress of our GALAXY trial, our clinical
development plans for ganetespib and the anticipated design of the Phase 3
portion of the GALAXY trial, reflect our current views with respect to future
events and are based on assumptions and subject to risks and uncertainties
that could cause actual results to differ materially from those expressed or
implied by such forward-looking statements. Those risks and uncertainties
include whether the results from the interim analysis of the Phase 2b portion
of the GALAXY trial will be consistent with future data from the Phase 2b
portion and the Phase 3 stage of the trial; whether the results at the
conclusion of the Phase 2b portion of the trial will demonstrate safety and
statistically significant efficacy; challenges with respect to patient
enrollment or other delays in our clinical development plans; as well as other
risks and uncertainties described in the "Risk Factors" section of our Form
10-K for the year ended December 31, 2011, as filed with the Securities and
Exchange Commission, including those under the heading “Risks Related to the
Development and Regulatory Approval of our Drug Candidates.” Synta undertakes
no obligation to publicly update forward-looking statements, whether because
of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7125
gfarmer@syntapharma.com
 
Press spacebar to pause and continue. Press esc to stop.